[go: up one dir, main page]

FR2865736B1 - Inhibiteurs de l'angiogenese, compositions les contenant et leur utilisation pour le traitement des maladies liees a une deregulation de l'angiogenese - Google Patents

Inhibiteurs de l'angiogenese, compositions les contenant et leur utilisation pour le traitement des maladies liees a une deregulation de l'angiogenese

Info

Publication number
FR2865736B1
FR2865736B1 FR0405954A FR0405954A FR2865736B1 FR 2865736 B1 FR2865736 B1 FR 2865736B1 FR 0405954 A FR0405954 A FR 0405954A FR 0405954 A FR0405954 A FR 0405954A FR 2865736 B1 FR2865736 B1 FR 2865736B1
Authority
FR
France
Prior art keywords
angiogenesis
deregulation
inhibitors
treatment
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0405954A
Other languages
English (en)
Other versions
FR2865736A1 (fr
Inventor
Daniele Mathieu
Jamal Temsamani
Michel Kaczorek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synt EM SA
Original Assignee
Synt EM SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0400964A external-priority patent/FR2865735B1/fr
Application filed by Synt EM SA filed Critical Synt EM SA
Priority to FR0405954A priority Critical patent/FR2865736B1/fr
Priority to CA002554822A priority patent/CA2554822A1/fr
Priority to US10/587,874 priority patent/US20070161553A1/en
Priority to JP2006550249A priority patent/JP2008505848A/ja
Priority to PCT/FR2005/000222 priority patent/WO2005075509A1/fr
Priority to AU2005210063A priority patent/AU2005210063A1/en
Priority to EP05717534A priority patent/EP1711521A1/fr
Publication of FR2865736A1 publication Critical patent/FR2865736A1/fr
Publication of FR2865736B1 publication Critical patent/FR2865736B1/fr
Application granted granted Critical
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR0405954A 2004-02-02 2004-06-02 Inhibiteurs de l'angiogenese, compositions les contenant et leur utilisation pour le traitement des maladies liees a une deregulation de l'angiogenese Expired - Fee Related FR2865736B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR0405954A FR2865736B1 (fr) 2004-02-02 2004-06-02 Inhibiteurs de l'angiogenese, compositions les contenant et leur utilisation pour le traitement des maladies liees a une deregulation de l'angiogenese
PCT/FR2005/000222 WO2005075509A1 (fr) 2004-02-02 2005-02-02 Inhibiteurs de l’angiogenese, compositions les contenant et leur utilisation pour le traitement des maladies liees a une deregulation de l’angiogenese
US10/587,874 US20070161553A1 (en) 2004-02-02 2005-02-02 Angiogenesis inhibitors, compositions containing same and use thereof for treating diseases related to angiogenetic deregulation
JP2006550249A JP2008505848A (ja) 2004-02-02 2005-02-02 血管新生阻害剤、それらを含む組成物及び血管新生障害に関連する疾患の治療におけるそれらの使用
CA002554822A CA2554822A1 (fr) 2004-02-02 2005-02-02 Inhibiteurs de l`angiogenese, compositions les contenant et leur utilisation pour le traitement des maladies liees a une deregulation de l`angiogenese
AU2005210063A AU2005210063A1 (en) 2004-02-02 2005-02-02 Angiogenesis inhibitors, compositions containing same and use thereof for treating diseases related to angiogenetic deregulation
EP05717534A EP1711521A1 (fr) 2004-02-02 2005-02-02 Inhibiteurs de l'angiogenese, compositions les contenant et leur utilisation pour le traitement des maladies liees a une deregulation de l'angiogenese

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0400964A FR2865735B1 (fr) 2004-02-02 2004-02-02 Inhibiteurs de l'angiogenese, compositions les contenant et leur utilisation pour le traitement des maladies liees a une deregulation de l'angiogenese
FR0405954A FR2865736B1 (fr) 2004-02-02 2004-06-02 Inhibiteurs de l'angiogenese, compositions les contenant et leur utilisation pour le traitement des maladies liees a une deregulation de l'angiogenese

Publications (2)

Publication Number Publication Date
FR2865736A1 FR2865736A1 (fr) 2005-08-05
FR2865736B1 true FR2865736B1 (fr) 2006-07-14

Family

ID=34751806

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0405954A Expired - Fee Related FR2865736B1 (fr) 2004-02-02 2004-06-02 Inhibiteurs de l'angiogenese, compositions les contenant et leur utilisation pour le traitement des maladies liees a une deregulation de l'angiogenese

Country Status (7)

Country Link
US (1) US20070161553A1 (fr)
EP (1) EP1711521A1 (fr)
JP (1) JP2008505848A (fr)
AU (1) AU2005210063A1 (fr)
CA (1) CA2554822A1 (fr)
FR (1) FR2865736B1 (fr)
WO (1) WO2005075509A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11174220B2 (en) 2019-12-13 2021-11-16 Inspirna, Inc. Metal salts and uses thereof
US11214536B2 (en) 2017-11-21 2022-01-04 Inspirna, Inc. Polymorphs and uses thereof

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009049305A2 (fr) 2007-10-12 2009-04-16 Arqule, Inc. Composés de tétrazole substitués et leurs utilisations
FR2944020B1 (fr) * 2009-04-02 2011-06-10 Etat Francais Ministere De La Defense Service De Sante Des Armees Peptides fusion pour le traitement de traumatismes ou de maladies affectant le systeme nerveux central
DK2673363T3 (da) 2011-02-11 2017-11-13 Univ Rockefeller Behandling af angiogenesesygdomme
ES2941477T3 (es) 2012-08-13 2023-05-23 Univ Rockefeller Agonista de LXRbeta para el tratamiento de cáncer
AU2015204572B2 (en) 2014-01-10 2020-07-30 Inspirna, Inc. LXR agonists and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009657A2 (fr) * 1998-08-14 2000-02-24 President And Fellows Of Harvard College Methodes de modulation d'une angiogenese
FR2810985B1 (fr) * 2000-07-03 2004-12-24 Synt Em Peptides lineaires amphipathiques et les compositions les contenant
EP1592457B1 (fr) * 2003-01-27 2012-07-25 Endocyte, Inc. Conjugue de la vinblastine et du folate en tant que medicament

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11214536B2 (en) 2017-11-21 2022-01-04 Inspirna, Inc. Polymorphs and uses thereof
US11174220B2 (en) 2019-12-13 2021-11-16 Inspirna, Inc. Metal salts and uses thereof
US11459292B2 (en) 2019-12-13 2022-10-04 Inspirna, Inc. Metal salts and uses thereof
US11878956B2 (en) 2019-12-13 2024-01-23 Inspirna, Inc. Metal salts and uses thereof
US12258303B2 (en) 2019-12-13 2025-03-25 Inspirna, Inc. Metal salts and uses thereof

Also Published As

Publication number Publication date
EP1711521A1 (fr) 2006-10-18
FR2865736A1 (fr) 2005-08-05
US20070161553A1 (en) 2007-07-12
JP2008505848A (ja) 2008-02-28
CA2554822A1 (fr) 2005-08-18
WO2005075509A1 (fr) 2005-08-18
AU2005210063A1 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
MA27334A1 (fr) Utilisation d'inhibiteurs de l'ikb kinase dans le traitement de la douleur
FR13C0029I2 (fr) Compositions pour le traitement de troubles gastro-intestinaux
EP2073811A4 (fr) Inhibiteurs de kinase utiles pour le traitement de maladies myéloproliférantes et d'autres maladies proliférantes
MA25820A1 (fr) Combinaisons d'inhibiteurs de peptidase iv de dipeptidyle et d'autres agents antidiabetiques pour le traitement du mellitus de diabete.
EP1631269A4 (fr) Methodes et compositions destinees a l'administration de butanes catecholiques pour le traitement de l'obesite
EP1638950A4 (fr) Derives de cyclohexylglycine servant d'inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
FR2833490B1 (fr) Utilisition cosmetique d'au moins une hydrophobine pour le traitement des matieres keratiniques et compositions mises en oeuvre
FR2854074B1 (fr) Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
EP2010572A4 (fr) Compositions contenant des polypeptides hpv et des peptides d'immunostimulation pour le traitement et la prévention du cancer du col de l'utérus
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
MA29030B1 (fr) 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation
DE60204951D1 (de) Ccr5 antagonisten verwendbar für die behandlung von aids
EP1604664A4 (fr) Medicament pour la prevention et le traitement de l'arteriosclerose et de l'hypertension
EP1771188A4 (fr) Methodes et compositions destinees au traitement de l'obesite, de maladies associees a l'insuline et de l'hypercholesterolemie
FR2869540B1 (fr) Compositions pharmaceutiques contenant des derives de b-carboline, et leur utilisation pour le traitement des cancers
FR2815541B1 (fr) Utilisation d'inhibiteurs de l'apoptose des pericytes pour le traitement et/ou la prevention de la retinopathie diabetique
DZ3027A1 (fr) Composés et procédés pour le traitement de l'asthme, de l'allergie et des troubles inflammatoires.
SE0302304D0 (sv) Novel compounds
MA26899A1 (fr) PREPARATIONS CONTENANT UN MEDICAMENT GLUCOCORTICOiDE POUR LE TRAITEMENT DES MALADIES BRONCHOPULMONAIRES.
FR2865736B1 (fr) Inhibiteurs de l'angiogenese, compositions les contenant et leur utilisation pour le traitement des maladies liees a une deregulation de l'angiogenese
EP1750513A4 (fr) Utilisation de ligands gpcr54 pour le traitement de l'infertilite
FR2860154B1 (fr) Composition pour le traitement de la mauvaise haleine
FR2857597B1 (fr) Utilisation de conjugues peptidiques pour la preparation de compositions destinees au traitement preventif et curatif de l'alopecie.
FR2800614B1 (fr) Composition pour le traitement des infections des voies respiratoires
FR2835851B1 (fr) Composition pour le traitement d'alliages de magnesium

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20110228